# A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)

> **NCT04153565** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 19 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT04153565
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-09
- **Primary completion:** 2022-09-21
- **Final completion:** 2022-09-21
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04153565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04153565, "A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04153565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*